Lifecore Biomedical financials
$6.59+1.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 May 25 | FY24 May 26 | FY23 May 28 |
|---|---|---|---|
| Revenue | $128.9M | $128.3M | $103.3M |
| Gross profit | $40.3M | $41.9M | $28.0M |
| Gross margin | 31.3% | 32.6% | 27.1% |
| Operating income | -$10.3M | -$8.8M | -$23.9M |
| Net income | -$44.4M | $12.0M | -$99.6M |
| Net margin | −34.4% | 9.4% | −96.4% |
| Diluted EPS | $-1.27 | $0.33 | $-3.32 |
| EBITDA | -$4.0M | $766.0K | -$6.5M |
| Operating cash flow | -$206.0K | $257.0K | -$17.4M |
| Free cash flow | -$13.6M | -$18.1M | -$38.9M |
| Diluted shares | 34.8M | 36.7M | 30.0M |
Balance sheet
| Period end | Mar 31 | May 25 | May 26 | May 28 |
|---|---|---|---|---|
| Cash & equivalents | $20.8M | $8.3M | $8.5M | $19.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.6M | $127.0M | $123.7M | $101.6M |
| Total assets | $225.5M | $239.3M | $254.0M | $253.5M |
| Total liabilities | $204.7M | $191.9M | $200.1M | $218.5M |
| Shareholders' equity | -$28.4M | $1.3M | $11.3M | -$4.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology